RESUMO
CONTEXTO E OBJETIVO: Para monitorar o controle glicêmico dos diabéticos, é recomendado medir regularmente a hemoglobina glicada (HbA1c). Isso pode ser difícil em locais distantes sem acesso a laboratórios. Uma alternativa é usar aparelhos portáteis à beira do leito do paciente. Nosso estudo visou avaliar o desempenho de um deles: A1CNow+, da Bayer. Following these results, the American Diabetes Association (ADA) and other national bodies issuing guidelines for diabetes treatment recommended that one primary goal of therapy should be to maintain HbA1c below 7%. 9 The ADA also recommended that HbA1c testing should be performed at least biannually in all patients and quarterly for patients whose therapy has changed or who are not meeting treatment goals. 9 Brazilian recommendations advise one measurement per patient every three months. 6 However, in many regions of Brazil, these recommendations are difficult to achieve because of a lack of medical analysis laboratories able to meet patients' needs, especially in areas distant from urban centers. This is the case in the state of Pernambuco, in the northeastern region of Brazil, even though the ESF is well established there. Moreover, this situation is not specific to Brazil but can be found in many developing countries where there are remote places with poor access to infrastructure and healthcare professionals. Therefore, HbA1c measurement by means of point-of-care testing (PoCT), directly performed by primary care unit staff, could be a useful alternative to measurement at a medical analysis laboratory.
OBJECTIVE
The aim of this study was to assess the performance of A1CNow+, a PoCT device from Bayer (São Paulo, Brazil), in comparison with the Vitros 5,1 FS method, an immunoturbidimetric laboratory method used in a university hospital in Recife, Pernambuco.
Specifically, the objective was to determine whether it could constitute a useful alternative to laboratory measurement, in order to monitor diabetes control in primary care units in remote areas.
Our hypothesis was that values of HbA1c given by the PoCT device would be close enough to values given by the immunoturbidimetric method to allow correct decision-making for blood glucose control, in terms of possible modifications of antidiabetic treatments (pharmacological or non-pharmacological).
METHODS
A cross-sectional accuracy study was conducted between June Fifty-five patients accepted the invitation to participate.
All of them provided informed consent and completed a short questionnaire to gather their baseline characteristics. Then, a venous blood test was performed by a hospital nurse and sent to the hospital laboratory for HbA1c to be measured using the Vitros 5,1 FS method, which was the current HbA1c measurement method used at the hospital and therefore used as the reference against which we evaluated the A1CNow+. The It is approved for commercialization in Brazil.
To assess the reproducibility of A1CNow+ measurements, their coefficient of variation (defined as the ratio of the standard deviation to the mean) was calculated using the measurements performed on each patient. For this calculation, only results from patients from whom we obtained at least two valid HbA1c measurements were taken into consideration. We did not use weighted means because of their lack of impact in this study.
Bland and Altman analysis was used to assess agreement between the two methods. 11 According to these authors, this analysis requires a sample size of at least 50 units, which determined our choice of number of patients. The differences between the methods (A1CNow+ minus Vitros 5,1 FS) were plotted against the average of the two measurements. The size of the differences and their distribution around zero were tested.
Finally, to assess the clinical usefulness of A1CNow+, its sensitivity and specificity were calculated in relation to the threshold of 7%, which is the usually recommended limit for diabetes control. The mean duration of diabetes was 10.1 ± 8.6 years; 85.5% of the patients were using oral antidiabetic agents and 30.9%
were taking insulin injections, alone or combined with oral antidiabetic therapy.
From the laboratory method, the mean for HbA1c measurements was 7.26 ± 1.87%. From A1CNow+, the mean for HbA1c measurements was 7.93 ± 1.97%, just considering the first measurement, and 7.91 ± 1.89% considering all measurements. The coefficient of variation for repeated measurements on the same patient was 3.6%. Bland-Altman analysis of accuracy showed that the mean difference between the A1CNow+ and the Vitros 5,1 FS determinations was +0.67% (95% confidence interval, CI:
+0.52% to +0.81%) and the standard deviation of the differences was 0.56%, such that A1CNow+ consistently gave higher measurements than the laboratory method (Figure 1) . The lower and upper limits of agreement of the graph were -0.45% (95% CI:
-0.71% to -0.19%) and +1.79 (95% CI: +1.52 to +2.05). The sensitivity was 100% and specificity was 67.7% in relation to the 7% level ( Table 1) . It appeared that 18.2% of the patients (10 patients)
were "incorrectly classified" using the analyzer. All of them were "false positive": they had HbA1c ≥ 7% with A1CNow+, whereas their HbA1c was < 7% with the Vitros 5,1 FS method.
DISCUSSION
PoCT has been advocated with the objective, among others, of promoting faster professional decisions and facilitating patients' adherence to medical counseling. 12 Indeed, in case of diabetes, studies have shown the benefits of rapid HbA1c results at the time of the patient's visit by improving glucose control through intensification of therapy, 13, 14 although controversy currently exists regarding this evidence and the analytical quality relative to laboratory testing. 15 Another potential advantage of PoCT is as a replacement for laboratory measurements in contexts in which laboratory facilities are scarce and often concentrated in urban areas, thus limiting access to populations and jeopardizing quality of care. 16, 17 This is the case in many developing countries, and Brazil, with its continental dimensions, is no exception. However, PoCT devices need to be proven to provide sufficiently reliable measurements in order to be recommended for use in cases of lack of or difficulty in access to laboratory services. 18 The present study investigated the analytical performance of the PoCT A1CNow+, a device that has been approved for use in Brazil, comparing it with the Vitros 5,1 FS laboratory method. The latter acted as our reference method, since it is the method used in the state university hospital where we conducted this evaluation, which is the reference hospital for diabetes in the state of Pernambuco.
The coefficient of variation of the A1CNow+ device was found to be 3.6%. This result was in agreement with some previous reports, 19 and lower than other results. 20 Although it has been recommended that HbA1c assays should have a coefficient of variation of < 2%, 21 this criterion is very strict and difficult to meet, even for certain laboratory-based methods. 22 It would therefore seem inappropriate to impose this goal on PoCT devices measuring HbA1c. Earlier reports recommended that
HbA1c assays should have a coefficient of variation of < 5% (ideally < 3%), 23 in which case our study revealed the A1CNow+ device to be satisfactory in terms of reproducibility. which was used in the DCCT and the UKPDS studies. 7, 8 Nonetheless, it is important to note that we compared A1CNow+ with the laboratory method that was used in the reference hospital for diabetes in Pernambuco, which ensures highly specialized care for diabetic patients from all over the state. Therefore, there is reason to suppose that the hospital would use a high-standard laboratory method for assessing one of the most important parameters for monitoring blood glucose control.
In keeping with the higher readings in relation to the laboratory method, the A1CNow+ device had good sensitivity (100%). 
CONCLUSION
According to the results from our study, A1CNow+ cannot be recommended for replacing laboratory measurements of HbA1c for glycemic control monitoring among diabetic patients, because the accuracy and specificity of its measurements were insufficient, compared with the method used in a reference university hospital. Further research is needed in order to compare its results with those obtained from a HPLC reference laboratory method, and/or to assess whether it could be used with the aid of a correction equation.
